WO2024086963A1 - Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice - Google Patents

Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice Download PDF

Info

Publication number
WO2024086963A1
WO2024086963A1 PCT/CN2022/126948 CN2022126948W WO2024086963A1 WO 2024086963 A1 WO2024086963 A1 WO 2024086963A1 CN 2022126948 W CN2022126948 W CN 2022126948W WO 2024086963 A1 WO2024086963 A1 WO 2024086963A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
eimd
subject
use according
cfu
Prior art date
Application number
PCT/CN2022/126948
Other languages
English (en)
Inventor
Ying-Chieh Tsai
Chi-Chang Huang
Li-hao CHENG
Chien-Chen Wu
Chih-Chieh Hsu
Original Assignee
Bened Biomedical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bened Biomedical Co., Ltd. filed Critical Bened Biomedical Co., Ltd.
Priority to PCT/CN2022/126948 priority Critical patent/WO2024086963A1/fr
Publication of WO2024086963A1 publication Critical patent/WO2024086963A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • compositions comprising probiotics, in particular, to compositions and methods for preventing or minimizing exercise-induced muscle damage.
  • EIMD Exercise-induced muscle damage
  • CRP C-reactive protein
  • MDA malondialdehyde
  • a lactic acid bacterium has been identified to be effective in protecting a subject for exercise by, e.g., reducing muscle damage, reducing inflammation, and assisting recovery from fatigue, thereby improving exercise performance in the subject.
  • the lactic acid bacterium is Lactobacillus paracasei PS23 (also referred herein to as L. paracasei PS23 or PS23) deposited under DSMZ Accession No. 32322.
  • the present disclosure provides a composition for use in preventing or minimizing EIMD in a subject in need thereof, wherein the composition comprises an effective amount of a lactic acid bacterium and a carrier thereof.
  • the lactic acid bacterium is L. paracasei PS23.
  • the lactic acid bacterium in the composition is in a form selected from the group consisting of a live strain, a heat-killed strain, a culture, a lysate, an extract, and any combination thereof.
  • the lactic acid bacterium is heat-killed PS23.
  • the composition is administered to the subject at an amount of at least 1 ⁇ 10 6 colony-forming unit (CFU) of the lactic acid bacterium per day.
  • CFU colony-forming unit
  • the effective amount of PS23 is at least 1 ⁇ 10 6 CFU, at least 1 ⁇ 10 7 CFU, at least 1 ⁇ 10 8 CFU, at least 1 ⁇ 10 9 CFU, at least 1 ⁇ 10 10 CFU or at least 1 ⁇ 10 11 CFU, including 5 ⁇ 10 6 CFU, 5 ⁇ 10 7 CFU, 5 ⁇ 10 8 CFU, 2 ⁇ 10 9 CFU, 3 ⁇ 10 9 CFU, 4 ⁇ 10 9 CFU, 5 ⁇ 10 9 CFU, 6 ⁇ 10 9 CFU, 7 ⁇ 10 9 CFU, 8 ⁇ 10 9 CFU, 9 ⁇ 10 9 CFU, 2 ⁇ 10 10 CFU, 3 ⁇ 10 10 CFU, 4 ⁇ 10 10 CFU, 5 ⁇ 10 10 CFU, 6 ⁇ 10 10 CFU, 7 ⁇ 10 10 CFU, 8 ⁇ 10 10 CFU, 9 ⁇ 10 10 CFU, 2 ⁇ 10 11 CFU, 3 ⁇ 10
  • preventing or minimizing EIMD comprises at least one of enhancing muscle strength, increasing muscle endurance, delaying or reducing muscle fatigue, accelerating muscle recovery from EIMD, and preventing or attenuating DOMS.
  • the composition is for use in further enhancing physical capacity, improving exercise performance, reducing inflammation, and/or reducing oxidation stress in the subject.
  • the present disclosure also provides a method of preventing or minimizing EIMD in a subject in need thereof, comprising administering to the subject a composition comprising an effective amount of PS23 and a carrier thereof.
  • the method further comprises enhancing physical capacity, improving exercise performance, reducing inflammation, and/or reducing oxidation stress in the subject.
  • the composition modulates a serum level of at least one biomarker associated with muscle damage, oxidative stress, inflammation, or anabolic hormones in the subject.
  • an increase of at least one of creatine kinase (CK) , myoglobin, thiobarbituric acid reactive substances (TBARS) , and high-sensitivity C-reactive protein (hs-CRP) resulted from EIMD is suppressed in the subject.
  • CK creatine kinase
  • TBARS thiobarbituric acid reactive substances
  • hs-CRP high-sensitivity C-reactive protein
  • a reduction of testosterone resulted from EIMD is suppressed in the subject.
  • the composition may be a nutritional composition, a food product, or a pharmaceutical composition.
  • the composition is in a form suitable for oral administration.
  • the composition is in a form of a concentrate, a paste, a powder, a suspension, a granule, a tablet, a pill, a capsule, a drink, or a dairy product.
  • the lactic acid bacterium serves as a sole active ingredient in the composition for preventing or minimizing EIMD. In some embodiments, the lactic acid bacterium may be in combination with an additional active ingredient for preventing or minimizing EIMD.
  • the composition may be administered to the subject 1 to 4 times per day or 1 to 4 times per week.
  • the composition is administered to the subject with a frequency selected from the group consisting of once per week, 2 times per week, 3 times per week, 4 times per week, once every three days, 2 times every three days, once every two days, once per day, 2 times per day, 3 times per day, and 4 times per day.
  • the composition is administered to the subject for at least one week.
  • the composition is administered to the subject for at least one week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 11 weeks, or at least 12 weeks.
  • the composition provided in the present disclosure is effective in reducing inflammation and oxidative stress, as well as improving exercise performance and fighting fatigue. Therefore, by administering the composition, the method of the present disclosure not only provides the benefits of muscle damage recovery, but also enhances physical performance that includes increasing muscle strength, muscle endurance, and physical capacity.
  • FIG. 1 shows the experimental procedure performed in the present disclosure.
  • the “star” indicates exercise-induced muscle damage
  • the “circles” indicate before/after (pre-EIMD) tests that include body composition, dietary record, blood biochemical, CMJ, IMTP and Wingate
  • the “triangles” indicate exercise performance test (CMJ, IMTP, Wingate) and assessments of blood biomarkers of muscle damage, inflammation, oxidative stress and anabolic hormones.
  • FIGs. 2A to 2C show the effects of 6-week L-PS23 and HK-PS23 supplementation on the changes in rate of force development (RFD) (FIG. 2A) , relative peak force (FIG. 2B) and jump height (FIG. 2C) , measured by countermovement jump assessment (CMJ) at pre-EIMD and 3 h, 24 h, and 48 h post-EIMD.
  • RTD rate of force development
  • FIG. 2B relative peak force
  • CMJ countermovement jump assessment
  • Different superscript letters (a, b) indicate significant difference between the groups at the same time point (p ⁇ 0.05) , and *indicates that each group is significantly different from pre-EIMD at different time points (p ⁇ 0.05) .
  • Placebo the placebo group
  • L-PS23 the live L. paracasei PS23 group
  • HK-PS23 the heat-killed L. paracase
  • FIGs. 3A and 3B show the effects of 6-week L-PS23 and HK-PS23 supplementation on the changes in relative peak force (FIG. 3A) and peak rate of force development (RFD) (FIG. 3B) , measured by isometric mid-thigh pull (IMTP) test at pre-EIMD and 3 h, 24 h, and 48 h post-EIMD.
  • Different superscript letters (a, b, c) indicate significant difference between the groups at the same time point (p ⁇ 0.05) , and *indicates that each group is significantly different from pre-EIMD at different time points (p ⁇ 0.05) .
  • Placebo the placebo group
  • L-PS23 the live L. paracasei PS23 group
  • HK-PS23 the heat-killed L. paracasei PS23 group.
  • FIGs. 4A to 4C show the effects of 6-week L-PS23 and HK-PS23 supplementation on the changes in relative mean power (FIG. 4A) , relative peak power (FIG. 4B) and fatigue index (FIG. 4C) , measured by Wingate test at pre-EIMD and 3 h, 24 h, and 48 h post-EIMD.
  • Different superscript letters (a, b, c) indicate significant difference between the groups at the same time point (p ⁇ 0.05) , and *indicates that each group is significantly different from pre-EIMD at different time points (p ⁇ 0.05) .
  • Placebo the placebo group
  • L-PS23 the live L. paracasei PS23 group
  • HK-PS23 the heat-killed L. paracasei PS23 group.
  • compositions, methods, and respective component (s) thereof are included in the present disclosure, yet open to the inclusion of unspecified elements or steps, whether essential or not.
  • the term “about” generally means within 10%, 5%, 1%, or 0.5%of a given value or range. Alternatively, the term “about” means within an acceptable standard error of the mean when considered by one of ordinary skill in the art. Unless otherwise expressly specified, all of the numerical ranges, amounts, values and percentages such as those for quantities of materials, durations of time periods, temperatures, operating conditions, ratios of amounts, and the likes disclosed herein should be understood as modified in all instances by the term “about. ”
  • the present disclosure provides a composition for use in preventing or minimizing EIMD in a subject in need thereof, wherein the composition comprises an effective amount of a lactic acid bacterium and a carrier thereof.
  • the lactic acid bacterium is L. paracasei PS23, which has been deposited under Budapest Treaty at Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Inhoffenstr. 7 B, D-38124 Braunschweig, Germany) and has been given the DSMZ Accession No. DSM 32322 by the International Depositary Authority.
  • an effective amount refers to the amount of an active ingredient (e.g., PS23) that confers a desired effect (e.g., preventing or minimizing EIMD) on the treated subject. Effective doses will vary, as recognized by one of ordinary skill in the art, depending on routes of administration, excipient usage, the possibility of co-usage with other treatment, and the condition to be treated.
  • the effective amount of PS23 may be at least 1 ⁇ 10 6 CFU, at least 1 ⁇ 10 7 CFU, at least 1 ⁇ 10 8 CFU, at least 1 ⁇ 10 9 CFU, at least 1 ⁇ 10 10 CFU or at least 1 ⁇ 10 11 CFU.
  • the effective amount of PS23 may range from about 1 ⁇ 10 6 CFU to about 1 ⁇ 10 13 CFU, about 1 ⁇ 10 6 CFU to about 1 ⁇ 10 12 CFU, about 1 ⁇ 10 6 CFU to about 1 ⁇ 10 11 CFU, about 1 ⁇ 10 6 CFU to about 1 ⁇ 10 10 CFU, about 1 ⁇ 10 7 CFU to about 1 ⁇ 10 13 CFU, about 1 ⁇ 10 7 CFU to about 1 ⁇ 10 12 CFU, about 1 ⁇ 10 7 CFU to about 1 ⁇ 10 11 CFU, about 1 ⁇ 10 7 CFU to about 1 ⁇ 10 10 CFU, about 1 ⁇ 10 8 CFU to about 1 ⁇ 10 13 CFU, about 1 ⁇ 10 8 CFU to about 1 ⁇ 10 12 CFU, about 1 ⁇ 10 8 CFU to about 1 ⁇ 10 11 CFU or about 1 ⁇ 10 8 CFU to about 1 ⁇ 10 10 CFU.
  • the term “preventing” or “prevention” refers to preventive or avoidance measures for a disease or a disorder or symptoms or conditions thereof, which include, but are not limited to, applying or administering one or more active agents to a subject who has not yet been diagnosed as a patient suffering from the disease or the disorder or the symptoms or conditions thereof but may be susceptible or prone to the disease or the disorder or the symptoms or conditions thereof.
  • the purpose of the preventive or avoidance measures is to avoid, prevent, or postpone the occurrence of the disease or the disorder or the symptoms or conditions thereof.
  • the term “subject” means a human or animal.
  • the subject include, but are not limited to, a rodent, a murine, a monkey, a guinea pig, a dog, a cat, a cow, a sheep, a pig, a horse, a rabbit, and a human.
  • the subject is a mammal, e.g., a primate such as a human.
  • the term “administering” or “administration” refers to the placement of an active ingredient into a subject by a method or route which results in at least partial localization of the active ingredient at a desired site to produce a desired effect.
  • the composition of the present disclosure is a nutritional composition, a food product, or a pharmaceutical composition and can be in any form suitable for oral administration.
  • the composition may be in a form of a concentrate, a paste, a powder, a suspension, a granule, a tablet, a pill, a capsule, a drink, or a dairy product.
  • the nutritional composition may also include a dietary supplement and/or a functional food.
  • a dietary supplement designates a product made from compounds usually used in foodstuffs, but which is in the form of tablets, powder, capsules, potion or any other form usually not associated with aliments, and which has beneficial effects for one’s health.
  • the “functional food” is an aliment which also has beneficial effects for one’s health.
  • the dietary supplement and the functional food can have a protective or curative effect against a disease or a disorder or the symptoms or conditions thereof.
  • carrier refers to compounds, materials, compositions, and/or dosage forms which are suitable for use in contact with the tissues of a subject.
  • the carrier is “acceptable” in the sense that it is compatible with the active ingredient (e.g., PS23) of the composition of the present disclosure (and capable of stabilizing the active ingredient) and not deleterious to the subject to be treated.
  • Examples of carriers include colloidal silicon oxide, cellulose, microcrystalline cellulose, sodium lauryl sulfate, polyethylene glycol (PEG) , alkylene glycol, sebacic acid, dimethyl sulfoxide, an alcohol, magnesium stearate, calcium stearate, gelatin, fat, glycerin, dietary fiber, alginate, pectin, carrageenan, amidated pectin, xanthan, gellan, karaya gum, rhamsan, welan, gum ghatti, and gum arabic.
  • PEG polyethylene glycol
  • alkylene glycol alkylene glycol
  • sebacic acid dimethyl sulfoxide
  • dimethyl sulfoxide dimethyl sulfoxide
  • an alcohol magnesium stearate, calcium stearate
  • gelatin fat, glycerin, dietary fiber, alginate, pectin, carrageenan, amidated pectin, xanthan, gellan, karay
  • composition provided in the present disclosure may modulate a serum level of at least one biomarker associated with muscle damage, oxidative stress, inflammation, or anabolic hormones in a subject, thereby effectively reducing inflammation and oxidative stress following exercise, as well as improving exercise performance and fighting fatigue.
  • fatigue refers to skeletal muscle fatigue and/or weakness. Muscle fatigue can be due to strenuous or repeated physical activity or exercise that has symptoms of fatigue, or affects myofibers and/or muscle function. Muscle fatigue may also be defined as the failure of exercise performance.
  • the biomarkers associated with muscle damage, oxidative stress, inflammation, and/or anabolic hormones include creatine kinase, myoglobin, thiobarbituric acid reactive substances (TBARS) , high-sensitivity C-reactive protein (hs-CRP) , and testosterone, but not limited thereto.
  • L. paracasei PS23 was isolated from healthy human feces and has been deposited under DSMZ Accession No. 32322.
  • the PS23 was inoculated in a culture medium, cultured at 37°C for 18 hours, harvested by centrifugation, and embedded and lyophilized with protective agents and excipients to form a live PS23 powder with a final concentration of 1 ⁇ 10 11 colony-forming unit (CFU) per gram.
  • CFU colony-forming unit
  • the PS23 was cultured as described above and heat-treated at 80°C for 1 hour before centrifugation, and then embedded and lyophilized with protective agents and excipients to form a heat-killed PS23 powder with a final concentration of 1 ⁇ 10 11 cells per gram. Subsequently, the live and heat-killed L. paracasei PS23 powders were formulated into capsules, wherein the L-PS23 treatment capsule contained 10 billion (1 ⁇ 10 10 ) CFU of live PS23, and the HK-PS23 treatment capsule contained 10 billion cells of heat-killed PS23.
  • the placebo capsule contained only microcrystalline cellulose (MCC) and matched to the L-PS23 and HK-PS23 treatment capsule for size, color, and taste.
  • MMC microcrystalline cellulose
  • the study described herein used a double-blind design.
  • the experimental procedure was shown in FIG. 1. All subjects were asked to take two capsules per day for 6 weeks, in which the subjects of the L-PS23 group took the L-PS23 capsules (1 ⁇ 10 10 CFU/capsule, 2 capsules/day) , the subjects of the HK-PS23 group took the HK-PS23 capsules (1 ⁇ 10 10 cells /capsule, 2 capsules/day) , and the subjects of the placebo group took the placebo capsules (2 capsules/day) .
  • EIMD immediate exercise-induced muscle damage
  • BMI body mass index
  • CMJ countermovement jump
  • IMTP isometric mid-thigh pull
  • RFD rate of force development
  • Wingate Wingate anaerobic test.
  • EIMD For eliciting EIMD, all subjects were asked to perform 100 maximal vertical jumps. This method involved jumping every 4 seconds for 10 times as a group, for a total of 10 groups. All subjects were asked to bend their knees 90 degrees during each squat, and each subject’s maximum jump height was marked as the goal. The researchers encouraged the subjects to try their best to reach the maximum height target with each jump.
  • the CMJ was used to measure the maximum speed, strength, and explosiveness of the lower body. For this test, participants were asked to place their hands on their hips and stand with their feet on a Kistler force-measuring platform (9260AA, Kistler GmbH, Switzerland) . Afterwards, participants were instructed to squat until their knees were bent 90 degrees and then immediately jump as high as possible with maximum force. Each participant received 3 replicates. The CMJ data were obtained at designated points, and the instrument was calibrated for each participant’s weight. The measured parameters included rate of force development (RFD) , relative peak force, and jump height, wherein RFD is defined as the ability to generate force at a given time during rapid voluntary contractions and is often used to assess blast strength.
  • RFD rate of force development
  • the IMTP test has been shown to be a valid and reliable test of maximal lower extremity strength that is highly correlated with exercise performance and used for changes in explosive power and as a marker of fatigue.
  • IMTP Rack Kairos Strength, USA
  • force plate Model 9260AA, Kistler, Switzerland
  • CK creatine kinase
  • Venous blood was collected from subjects at pre-EIMD (i.e., after the 6-week sample intervention and before the EIMD elicitation) , and 3 h, 24 h and 48 h post-EIMD for biomarker assessments, including the biomarkers of muscle damage, inflammation, oxidative stress and anabolic hormones.
  • CK creatine kinase
  • hs-CRP high-sensitivity CRP
  • myoglobin and testosterone were analyzed by autoanalyzer (DXI 800, Beckman Coulter, Inc., CA, USA)
  • TBARS thiobarbituric acid reactive substances
  • the subject’s venous blood was collected before and after the 6-week sample intervention, and used for analyzing liver function, renal function, blood lipids and other indicators to evaluate the subjects’ metabolic and health status, thereby determining whether they were affected by the intervention. All the subjects were asked for fasting at least 8 hours, and the blood serum was assessed with an autoanalyzer (Hitachi 717, Tokyo, Japan) for the levels of aspartate transaminase (AST) , aminotransferase (ALT) , total cholesterol (TC) , triglyceride (TG) , high-density lipid-cholesterol (HDL-C) , low-density lipid-cholesterol (LDL-C) , blood urea nitrogen (BUN) , creatine (CREA) , uric acid (UA) and glucose.
  • AST aspartate transaminase
  • ALT aminotransferase
  • TC total cholesterol
  • TG triglyceride
  • Example 1 Effects on dietary intake and body composition before and after the 6-week L-PS23 or HK-PS23 intervention
  • Table 2 showed the subjects’ daily dietary intake (carbohydrate, protein, and fat) and total calories before and after six weeks of the intervention. The results indicated that there was no significant difference between the three groups, and there was no significant change in the before-after comparison within the group.
  • body composition the change to the subjects’ body composition before and after the intervention was reported in Table 3. It was shown that there were no significant differences in body weight, body mass index (BMI) , lean body mass (LBM) , and fat body mass (FBM) between the groups before and after six weeks of the intervention.
  • BMI body mass index
  • LBM lean body mass
  • FBM fat body mass
  • the body weight and BMI of the HK-PS23 group were significantly reduced as compared with the placebo and L-PS23 groups (p ⁇ 0.05)
  • BW body weight
  • BMI body mass index
  • LBM lean body mass
  • FBM fat body mass
  • Example 2 Effects on biochemical characteristics before and after 6-week L-PS23 or HK-PS23 intervention
  • liver function indexes AST and ALT
  • renal function indexes BUN, CREA, and UA
  • blood lipid metabolism indexes TC, TG, HDL-C, and LDL-C
  • blood sugar were all within the normal range, and there was no significant difference between the three groups before or after the intervention.
  • AST aspartate aminotransferase
  • ALT alanine transaminase
  • TC total cholesterol
  • TG triacylglycerol
  • HDL-C high-density lipid-cholesterol
  • LDL-C low-density lipid-cholesterol
  • BUN blood urea nitrogen
  • CREA creatinine
  • UA uric acid
  • Example 3 Effects of L-PS23 and HK-PS23 supplementation on exercise performance
  • the vertical jump height was measured by countermovement jump assessment (CMJ) at 3 h, 24 h, and 48 h post-EIMD. It was found that the percentage changes in rate of force development (RFD) and relative peak force were significantly lower in all three groups, namely the placebo, L-PS23, and HK-PS23 groups, at 3 h, 24 h, and 48 h post-EIMD as compared with pre-EIMD (p ⁇ 0.05) (FIGs. 2A and 2B) .
  • FIG. 2A showed that the L-PS23 or HK-PS23 supplementation group had significantly less RFD loss and faster recovery than the placebo group at 24 and 48 hours after EIMD (p ⁇ 0.0001) , and the HK-PS23 group had significantly less RFD loss than the placebo group at 3 h post-EIMD (p ⁇ 0.05) .
  • the jump height in the L-PS23 and HK-PS23 supplementation groups had significantly less loss than the placebo group at 24 h post-EIMD (p ⁇ 0.05) .
  • these results indicated significant time effects for RFD, relative peak force and jump height (p ⁇ 0.0001) .
  • the L-PS23 and HK-PS23 groups had significantly less loss of peak RFD at 3 h and 24 h post-EIMD, and had significantly better recovery at 48 h post-EIMD than those of the placebo group (p ⁇ 0.05) (FIG. 3B) .
  • these results indicated significant time effects for relative peak force and peak RFD (p ⁇ 0.0001) .
  • the Wingate anaerobic test was used to evaluate the effects of lower limb muscle strength and anaerobic strength after EIMD.
  • By the Wingate anaerobic test at 3 h, 24 h, and 48 h post-EIMD it was found that in the placebo, L-PS23, and HK-PS23 groups, the percentage changes in relative mean power and relative peak power were significantly lower, and the percentage change in fatigue index was significantly greater, as compared with pre-EIMD (p ⁇ 0.0001) (FIGs. 4A to 4C) .
  • the L-PS23 and HK-PS23 groups had significantly less loss of relative mean power than the placebo group at 3 h, 24 h, and 48 h post-EIMD (p ⁇ 0.05) (FIG. 4A) .
  • the L-PS23 and HK-PS23 groups had significantly less loss of relative peak power than the placebo group at 24 h and 48 h post-EIMD (p ⁇ 0.05) .
  • FIG. 4A the fatigue index
  • both L-PS23 and HK-PS23 could significantly prevent the decrease in jump-related strength performance after EIMD and had better recovery effects, and could also improve the performance of Wingate’s anaerobic power.
  • Example 4 Effects of L-PS23 and HK-PS23 supplementation on biomarkers of muscle damage, inflammation, oxidative stress, and anabolic hormones
  • the TBARS increase ratios in the L-PS23 and HK-PS23 groups at 24 h and 48 h post-EIMD were significantly lower than the placebo group (p ⁇ 0.05)
  • the TBARS increase ratio in the HK-PS23 group at 3 h post-EIMD was also significantly lower than the placebo and L-PS23 groups (p ⁇ 0.05) .
  • the hs-CRP increase ratios in the L-PS23 and HK-PS23 groups at 24 h and 48 h post-EIMD were significantly lower than the placebo group (p ⁇ 0.05) , while at 48 h post-EIMD, the hs-CRP increase ratio in the HK-PS23 group was also significantly lower than the L-PS23 group (p ⁇ 0.0001) (FIG. 5D) .
  • the percentage changes of testosterone were significantly lower in the placebo, L-PS23, and HK-PS23 groups as compared with pre-EIMD (p ⁇ 0.0001) . Also, at 48 h post-EIMD, the percentage change of testosterone in the placebo group remained significantly lower than pre-EIMD, while the percentage changes of testosterone in the L-PS23 and HK-PS23 groups had recovered with no significant difference from pre-EIMD.
  • the HK-PS23 group had significantly less loss and faster recovery of the testosterone concentration than the placebo group at 3 h and 24 h post-EIMD (p ⁇ 0.05) , and also significantly less loss than those of the L-PS23 group at 24 h post-EIMD (p ⁇ 0.05) .
  • the probiotic composition comprising L. paracasei PS23, either live or heat-killed, provided in the present disclosure may improve exercise performance, such as reducing muscle strength loss, reducing the amount of biomarkers of muscle damage, inflammation, and oxidative stress in serum, and accelerating muscle damage repair, strength, and fatigue recovery. Also, the probiotic composition provided in the present disclosure may prevent or minimize EIMD.
  • the probiotic composition comprising HK-PS23 provided in the present disclosure is safer with longer shelf-life and is easier to transport and store.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition destinée à être utilisée pour prévenir ou réduire au minimum une lésion musculaire induite par l'exercice (EIMD) chez un sujet en ayant besoin. La composition comprend Lactobacillus paracasei PS23 et un support de celle-ci. L'invention concerne également un procédé pour prévenir ou réduire au minimum une EIMD par administration de la composition.
PCT/CN2022/126948 2022-10-24 2022-10-24 Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice WO2024086963A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/126948 WO2024086963A1 (fr) 2022-10-24 2022-10-24 Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/126948 WO2024086963A1 (fr) 2022-10-24 2022-10-24 Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice

Publications (1)

Publication Number Publication Date
WO2024086963A1 true WO2024086963A1 (fr) 2024-05-02

Family

ID=90829629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/126948 WO2024086963A1 (fr) 2022-10-24 2022-10-24 Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice

Country Status (1)

Country Link
WO (1) WO2024086963A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134690A1 (fr) * 2018-01-05 2019-07-11 Bened Biomedical Co., Ltd. Nouvelle bactérie lactique et ses applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134690A1 (fr) * 2018-01-05 2019-07-11 Bened Biomedical Co., Ltd. Nouvelle bactérie lactique et ses applications

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN, SHANG-MIN ET AL.: "Correlations between Gut Microbiota and Physical Activity-Related Injuries: a Literature Review", INJURY MEDICINE (ELECTRONIC EDITION), CN, vol. 11, no. 1, 31 March 2022 (2022-03-31), CN, pages 41 - 49, XP009554861, ISSN: 2095-1566, DOI: 10.3868/j.issn.2095-1566.2022.01.007 *
LI-HAN CHEN: "Lactobacillus paracasei PS23 decelerated age-related muscle loss by ensuring mitochondrial function in SAMP8 mice", AGING, vol. 11, no. 2, 29 January 2019 (2019-01-29), pages 756 - 770, XP093165698, ISSN: 1945-4589, DOI: 10.18632/aging.101782 *
LIU, HAIMING: "Research progress of probiotics supplement intervention on athletic performance", JOURNAL OF SHANDONG PHYSICAL EDUCATION INSTITUTE, CN, vol. 37, no. 5, 31 October 2021 (2021-10-31), CN, pages 83 - 90, XP009554862, ISSN: 1006-2076, DOI: 10.14104/j.cnki.1006-2076.2021.05.010 *
WU, MIN; LIU, ZUOHUA; QI, RENLI: "Growth and Development of Muscle in Animals Controlled by Intestinal Microbes", CHINESE JOURNAL OF ANIMAL NUTRITION, CN, vol. 31, no. 9, 31 December 2019 (2019-12-31), CN, pages 3976 - 3982, XP009554792, ISSN: 1006-267X, DOI: 10.3969/j.issn.1006-267x.2019.09.008 *

Similar Documents

Publication Publication Date Title
Fitschen et al. Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations
Ratamess et al. The effects of amino acid supplementation on muscular performance during resistance training overreaching
CN112118855A (zh) 体重管理组合物
US9101656B2 (en) Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time
RU2722270C2 (ru) Бактериальная композиция для применения в уменьшении ухудшения показателей после физической нагрузки
Matsui et al. Effect of a leucine-enriched essential amino acids mixture on muscle recovery
Clayton et al. Turmeric supplementation improves markers of recovery in elite male footballers: a pilot study
Cherniack Ergogenic dietary aids for the elderly
WO2024086963A1 (fr) Bactérie lactique et procédé pour prévenir ou réduire au minimum les lésions musculaires induites par l'exercice
US20230165868A1 (en) Paraxanthine-based compositions for enhancing muscle function, nitric oxide signaling, and/or muscle glycogen levels
US11504413B2 (en) Multi-nutrient composition
TWI847318B (zh) 用於預防或最小化運動所引起的肌肉損傷的乳酸菌及方法
TW202417024A (zh) 用於預防或最小化運動所引起的肌肉損傷的乳酸菌及方法
JP7154473B2 (ja) 疲労回復用および／または疲労蓄積予防用組成物
Baralić et al. Effect of combined antioxidant treatment on oxidative stress, muscle damage and sport performance in female basketball players
Sardar et al. Effect of exercise with and without pomegranate concentrate consumption on HbA1c and C-peptide levels: a study of middle-aged women with metabolic syndrome
US20230108723A1 (en) Multi-Nutrient Composition
Nandyantami et al. Difference Between Watermelon Juice and Pure L-citrulline on Muscle Soreness After Eccentric Exercise: A Comparative Study
US20210275622A1 (en) Methods of increasing muscular strength and muscular endurance with asparagus racemosus
Amorim et al. Supplements in Football
JP7093262B2 (ja) 高強度運動による疲労軽減・回復用組成物
US20220072070A1 (en) Method for improving walking capacity of elderly subjects
Mohtadinia et al. Effects of carnitine with and without glutamine supplementation on markers of muscle damage and muscle soreness among football players: a randomized controlled clinical trial
JP2018000046A (ja) 危機回避能力低下抑制剤
US20190125703A1 (en) Compound use in promoting energy expenditure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22962951

Country of ref document: EP

Kind code of ref document: A1